The ADCY2 antibody is a research tool designed to detect adenylate cyclase 2 (ADCY2), a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP), a key secondary messenger in cellular signaling. ADCY2 is part of the adenylate cyclase family (AC1–AC9) and is primarily expressed in the brain, where it plays a role in G protein-coupled receptor (GPCR)-mediated signaling pathways. It is involved in regulating neurotransmission, memory formation, and neuronal plasticity. Dysregulation of ADCY2 has been linked to neuropsychiatric disorders, such as bipolar disorder and schizophrenia, as well as cardiovascular diseases and certain cancers. The ADCY2 antibody is commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and function in tissues or cell lines. Many commercially available ADCY2 antibodies are validated for specificity using knockout controls or siRNA knockdown to ensure minimal cross-reactivity with other adenylate cyclase isoforms. Researchers utilize this antibody to explore ADCY2's role in cAMP-dependent pathways, its interaction with stimulatory or inhibitory G proteins, and its potential as a therapeutic target in disease models.